Before revision: In 2019, Arvinas put two PROTACs into clinical trials: ARV-110 , an androgen receptor degrader, and ARV-471 , an estrogen receptor degrader.
After revision: bavdegalutamide ()vepdegestrant ()In 2019, Arvinas put two PROTACs into clinical trials: ARV-110 , an androgen receptor degrader, and ARV-471 , an estrogen receptor degrader.